PTEN promoter methylation in sporadic thyroid carcinomas

Thyroid

Volumn 16, Issue 1, 2006, Pages 17-23

  Alvarez Nuñez, Francisco ^a   Bussaglia, Elena ^a   Mauricio, Didac ^a   Ybarra, Juan ^a   Vilar, Monica ^a   Lerma, Enrique ^a   De Leiva, Alberto ^a,b   Matias Guiu, Xavier ^a,c  

^a HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^b UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^c HOSPITAL UNIVERSITARI ARNAU DE VILANOVA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

GENOMIC DNA; MESSENGER RNA; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE;

ARTICLE; CARCINOGENESIS; CHROMOSOME 10Q; CONTROLLED STUDY; DNA METHYLATION; EPIGENETICS; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROMOTER REGION; THYROID ADENOMA; THYROID CARCINOMA; THYROID FOLLICULAR CARCINOMA; THYROID PAPILLARY CARCINOMA; TUMOR SUPPRESSOR GENE;

ADENOMA; CARCINOMA, PAPILLARY, FOLLICULAR; CYTOPLASM; DNA, NEOPLASM; HUMANS; IMMUNOHISTOCHEMISTRY; METHYLATION; PROMOTER REGIONS (GENETICS); PTEN PHOSPHOHYDROLASE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; THYROID NEOPLASMS;

EID: 33644749218     PISSN: 10507256     EISSN: None     Source Type: Journal    
DOI: 10.1089/thy.2006.16.17     Document Type: Article

References (41)

1. Pennisi E 1997 New tumor suppressor found-twice. Science 275:1876-1878.
2. Risinger JI, Hayes AK, Berchuck A, Barrett JC 1997 PTEN/MMAC1 Mutations in endometrial cancers. Cancer Res 57:4736-4738.
3. Steck PA, Pershouse MA, Jasser SA, Yung WK, Lin H, Ligon AH, Langford LA, Baumgard ML, Hattier T, Davis T, Frye C, Hu R, Swedlund B, Teng DH, Tavtigian SV 1997 Identification of candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. Nat Genet 15:356-362.
4. Gimm O 2001 Thyroid cancer. Cancer Lett 163:143-156.
5. Bussaglia E, Del Rio E, Matias-Guiu X, Prat J 2000 PTEN mutations in endometrial carcinomas: A molecular and clinicopathologic analysis of 38 cases. Hum Pathol 31:312-317.
6. Dahia PLM, Marsh DJ, Zheng Z, Zedenius J, Komminoth P, Frisk T, Wallin G, Parsons R, Longy M, Larsson C, Eng C 1997 Somatic deletions and mutations in the Cowden disease gene, PTEN, in sporadic thyroid tumors. Cancer Res 57:4710-4713.
7. Liaw D, Marsh DJ, Li J, Dahia PLM, Wang SI, Zheng Z, Bose S, Call KM, Tsou HC, Peacocke M, Eng C, Parsons R 1997 Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome. Nat Genet 16:64-67.
8. Nelen MR, van Staveren WCG, Peeters EAJ, Hassel MB, Gorlin RJ, Hamm H, Lindboe CF, Fryns JP, Sijmons RH, Woods DG, Mariman ECM, Padberg GW, Kremer H 1997 Germline mutations in PTEN/MMAC1 gene in patients with Cowden disease. Hum Mol Genet 6:1383-1387.
9. Li J, Yen C, Liaw D, Podsypanina K, Bose S, Wang S, Puc J, Miliaresis C, Rodgers L, McCombie R, Bigner SH, Giovanella BC, Ittman M, Tycko B, Hibshoosh H, Wigler MH, Parsons R 1997 PTEN a putative protein tyrosine phosphatase gene mutated in human brain, breast and prostate cancer. Science 275:1943-1947.
10. Gimm O, Attié-Bitach T, Lees JA, Vekemans M, Eng C 2000 Expression of the PTEN tumour suppressor protein during human development. Hum Mol Genet 9:1633-1639.
11. Downes CP, Bennett D, McConnachie G, Leslie NR, Pass I, MacPhee C, Patel L, Gray A 2001 Antagonism of PI3-kinase-dependent signalling pathways by the tumour suppressor protein, PTEN. Biochem Soc Trans 29:846-851.
12. Maehama T, Dixon JE 1999 PTEN, a tumour suppressor that functions as a phospholipids phosphatase. Trends Cell Biol 9:125-128.
13. Tallini G 2002 Molecular pathobiology of thyroid neoplasms. Endocr Pathol 13:271-288.
14. Gimm O, Chi H, Dahia PLM, Perren A, Hinze R, Komminoth P, Dralle H, Reynolds PR, Eng C 2001 Somatic mutation and germline variants of MINPP1, a phosphatase gene located in proximity to PTEN on 10q23.3, in follicular thyroid carcinomas. J Clin Endocrinol Metab 86:1801-1805.
15. Bussaglia E, Pujol RM, Gil MJ, Marti RM, Tuneu A, Febrer MI, Garcia-Patos V, Ruiz EM, Barnadas M, Alegre M, Serrano S, Matias-Guiu X 2002 PTEN mutations in eight Spanish families and one Brazilian family with Cowden syndrome. J Invest Dermatol 118:639-644.
16. Di Cristofano A, Pesce B, Cordon-Cardo C, Pandolfi PP 1998 Pten is essential for embryonic development and tumour suppression. Nat Genet 19:348-355.
17. Bruni P, Boccia A, Baldassarre G, Trapasso F, Santoro M, Chiappetta G, Fusco A, Viglietto G 2000 PTEN expression is reduced in a subset of sporadic thyroid carcinomas: Evidence that PTEN-growth suppressing activity in thyroid cancer cells mediated by p27kip1. Oncogene 19:3146-3155.
18. Gimm O, Perren A, Weng LP, Marsh DJ, Yeh JJ, Ziebold U, Gil E, Hinze R, Delbridge L, Lees JA, Mutter GL, Robinson BG, Komminoth P, Dralle H, Eng C 2000 Differential nuclear and cytoplasmatic expression of PTEN in normal thyroid tissue, and benign and malignant epithelial thyroid tumors. Am J Pathol 156:1693-1700.
19. Halachmi N, Halachmi S, Evron E, Cairns P, Okami K, Motosayu S, Westra WH, Zeiger MA, Jen J, Sidransky D 1998 Somatic mutations of the PTEN tumor suppressor gene in sporadic follicular thyroid tumors. Genes Chromosomes Cancer 23:239-243.
20. Yeh JJ, Marsh DJ, Zedenius J, Dwight T, Delbridge L, Robinson BG, Eng C 1999 Fine-structure deletion analysis of 10q22-24 demonstrates novel regions of loss and suggests that sporadic follicular thyroid adenomas and follicular thyroid carcinomas develop along distinct parallel neoplastic pathways. Genes Chromosomes Cancer 26:322-328.
21. Soria JC, Lee HY, Lee JI, Wang L, Issa JP, Kemp BL, Liu DD, Kurie JM, Mao L, Khuri FR 2002 Lack of PTEN expression in non-small cell lung cancer could be related to promoter methylation. Clin Cancer Res 8:1178-1184.
22. Zysman MA, Chapman WB, Bapat B 2002 Considerations when analyzing the methylation status of PTEN tumor supressor gene. Am J Pathol 160:795-800.
23. Zhou XP, Gimm O, Hampel H, Niemann T, Walker MJ, Eng C 2000 Epigenetic PTEN silencing in malignant melanomas without PTEN mutation. Am J Pathol 157:1123-1128.
24. Fujii GH, Morimoto AM, Berson AE, Bolen JB 1999 Transcriptional analysis of the PTEN/MMAC1 pseudogene, psiPTEN. Oncogene 18:1765-1769.
25. Whang YE, Wu X, Sawyers CL 1998 Identification of a pseudogene that can masquerade as a mutant allele of the PTEN/MMAC1 tumor suppressor gene. J Natl Cancer Inst 90:859-861.
26. Herman JG, Graff JR, Myohanen S, Nelkin BD, Baylin SB 1996 Methylation-specific PCR: A novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci USA 93:9821-9826.
27. Salvesen HB, MacDonald N, Ryan A, Jacobs IJ, Lynch ED, Akslen LA, Das S 2001 PTEN methylation is associated with advanced stage and microsatellite instability in endometrial carcinoma. Int J Cancer 91:22-26.
28. Cameron EE, Bachman KE, Myohanen S, Herman JG, Baylin SB 1999 Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer. Nat Genet 21:103-107.
29. Strathdee G, Brown R 2002 Aberrant DNA methylation in cancer: Potential clinical interventions. Expert Reviews in Molecular Medicine, March 2002, www-ermm.cbcu.cam.ac.uk (Last accessed December 1, 2005).
30. Bird AP 1996 The relationship of DNA methylation to cancer. Cancer Surv 28:87-101.
31. Baeza N, Weller M, Yonekawa Y, Kleihues P, Ohgaki H 2003 PTEN methylation and expression in glioblastomas. Acta Neuropathol (Berl) 106:479-485.
32. Fan X, Munoz J, Sanko SG, Castresana JS 2002 PTEN, DMBT1, and p16 alterations in diffusely infiltrating astrocytomas. Int J Oncol 21:667-674.
33. Martini M, Ciccarone M, Garganese G, Maggiore C, Evangelista A, Rahimi S, Zannoni G, Vittori G, Larocca LM 2002 Possible involvement of hMLH1, p16 (INK4a) and PTEN in the malignant transformation of endometriosis. Int J Cancer 102:398-406.
34. Matias-Guiu X, Catasus L, Bussaglia E, Lagarda H, Garcia A, Pons C, Munoz J, Arguelles R, Machin P, Prat J 2001 Molecular pathobiology of endometrial hyperplasia and carcinoma. Hum Pathol 32:569-577.
35. Plumb JA, Strathdee G, Sludden J, Kaye SB, Brown R 2000 Reversal of drug resistance in human tumor xenografts by 2′-deoxy-5-azacytidine-induced demethylation of the hMLH1 gene promote. Cancer Res 60:6039-6044.
36. Chiurazzi P, Pomponi MG, Pietrobono R, Bakker CE, Neri G, Oostra BA 1999 Synergistic effect of histone hyperacetilation and DNA demethylation in the reactivation of the FMR1 gene. Hum Mol Genet 8:2317-2323.
37. Atweh GF, Sutton M, Nassif I, Boosalis V, Dover GJ, Wallenstein S, Wright E, McMahon L, Stamatoyannopoulos G, Faller DV, Perrine SP 1999 Sustained induction of fetal haemoglobin by pulse butyrate therapy in sickle cell disease. Blood 93:1790-1797.
38. Collins AF, Pearson HA, Giardina P, McDonagh KT, Brusilow SW, Dover GJ 1995 Oral sodium phenylbutyrate therapy in homozygous beta thalasemia: A clinical trial. Blood 85:43-49.
39. Fournel M, Sapieha P, Beaulieu N, Besterman JM, MacLeod AR 1999 Down-regulation of human DNA-(cytosine-5) methyltransferase induces cell cycle regulators p16(ink4A) and p21 (WAF7Cip1) by distinct mechanisms. J Biol Chem 274:24250-24256.
40. Ramchandani S, MacLeod AR, Pinard M, von Hofe E, Szyf M 1997 Inhibition of tumorigenesis by a cytosine-DNA, methyltransferase, antisense oligodeoxynucleotide. Proc Natl Acad Sci USA 94:684-689.
41. Podsypanina K, Lee RT, Politis C, Hennessy I, Crane A, Puc J, Neshat M, Wang H, Yang L, Gibbons J, Frost P, Dreisbach V, Blenis J, Gaciong Z, Fisher P, Sawyers C, Hedrick-Ellenson L, Parsons R 2001 An inhibitor of mTOR reduces neoplasia and normalizes p70/S6 kinase activity in PTEN+/-mice. Proc Natl Acad Sci USA 98:10320-10325.